Dr. Jeffrey S. Rumbyrt, M. D.

Medicare patients and services

Medicare patients, 2024

203

Services billed

5,389

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 166 payments worth $77,936 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 19 industry-funded studies in 2025, from 7 companies. The companies reported $646,245 in research payments for these studies, mostly to the institutions running them.

• Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
  Sanofi US Services Inc. · Completed · NCT06102005
• A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
  E.r. Squibb & Sons, L.l.c.
• A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
  Sanofi US Services Inc. · Completed · NCT06691113
• A multicentre, randomized, double-blind, placebo-controlled, dose find
  GlaxoSmithKline, LLC.
• A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
  AbbVie Inc. · Active, not recruiting · NCT06718101
• A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
  AstraZeneca Pharmaceuticals LP
• Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
  Sanofi US Services Inc. · Enrolling by invitation · NCT06609239
• A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
  Celgene Corporation
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  Sanofi US Services Inc. · Active, not recruiting · NCT06241118
• A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Allergy & Immunology clinicians in Lakewood

• Francine G. Andrews, M. D.
• Nicole E. Barberis, MD
• Susan Bargas, LPN
• Jagadish Boggavarapu, M.D.
• Peter J. Cvietusa
• Naomi M. Fieman, MD
• Suzanne L. Fishman, MD
• Shikha Gupta, MD